With mon­ey flow­ing, Pli­ant Ther­a­peu­tics heads to pub­lic well

Fresh off rais­ing a $100 mil­lion Se­ries C and send­ing their sec­ond com­pound in­to the clin­ic, Pli­ant Ther­a­peu­tics is head­ed for Wall Street.

The South San Fran­cis­co-based biotech filed this morn­ing for an $86 mil­lion IPO. The mon­ey will help fund clin­i­cal de­vel­op­ment of their lead pro­gram for a rare lung dis­ease and rare liv­er dis­ease and boost pre­clin­i­cal re­search for on­col­o­gy and mus­cu­lar dy­s­tro­phy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER